JP2007512341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512341A5 JP2007512341A5 JP2006541366A JP2006541366A JP2007512341A5 JP 2007512341 A5 JP2007512341 A5 JP 2007512341A5 JP 2006541366 A JP2006541366 A JP 2006541366A JP 2006541366 A JP2006541366 A JP 2006541366A JP 2007512341 A5 JP2007512341 A5 JP 2007512341A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- group
- pharmaceutical composition
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 62
- 125000005843 halogen group Chemical group 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000004429 atom Chemical group 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000001624 naphthyl group Chemical group 0.000 claims 9
- 125000002877 alkyl aryl group Chemical group 0.000 claims 7
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- -1 di-substituted piperidine Chemical class 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 229940089973 Sodium channel antagonist Drugs 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000472 muscarinic agonist Substances 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52473403P | 2003-11-21 | 2003-11-21 | |
| PCT/US2004/038669 WO2005051915A1 (en) | 2003-11-21 | 2004-11-18 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007512341A JP2007512341A (ja) | 2007-05-17 |
| JP2007512341A5 true JP2007512341A5 (https=) | 2008-01-10 |
Family
ID=34632928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541366A Withdrawn JP2007512341A (ja) | 2003-11-21 | 2004-11-18 | 神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070099950A1 (https=) |
| EP (1) | EP1687275A4 (https=) |
| JP (1) | JP2007512341A (https=) |
| CN (1) | CN1882546A (https=) |
| AU (1) | AU2004292546A1 (https=) |
| CA (1) | CA2545786A1 (https=) |
| WO (1) | WO2005051915A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| WO2006127329A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Quinoline derivatives useful as modulators of ion channels |
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| EP3646886B1 (en) * | 2017-06-28 | 2023-10-04 | Osaka University | Treatment of pain with serotonin-3 receptor agonist |
| CN107721925B (zh) * | 2017-09-12 | 2020-02-14 | 上海交通大学 | 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用 |
| GB2568291A (en) * | 2017-11-13 | 2019-05-15 | Crisby Milita | New use |
| CN114149410B (zh) * | 2020-09-07 | 2025-02-25 | 四川科伦博泰生物医药股份有限公司 | 吡啶并环类化合物及其制备方法和用途 |
| CN112300071B (zh) * | 2020-11-25 | 2023-01-31 | 威胜生物医药(苏州)股份有限公司 | 一种高纯度磷酸氯喹的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2077249A (en) * | 1934-06-06 | 1937-04-13 | Winthrop Chem Co Inc | Basically substituted acridine compounds |
| US3066141A (en) * | 1957-04-26 | 1962-11-27 | Jr Ralph Jones | Quinoline-type mustards and process for producing same |
| US5021426A (en) * | 1990-02-26 | 1991-06-04 | Merck & Co., Inc. | Method of traeting malaria with cyproheptadine derivatives |
| EP0446604A3 (en) * | 1990-03-16 | 1992-02-19 | American Cyanamid Company | Pyridine and related aza heterocycle derivatives as cardiovascular agents |
| FR2676228B1 (fr) * | 1991-05-07 | 1995-01-06 | Rhone Poulenc Chimie | Procede de preparation de sulfate de chloroquine. |
| WO1996039818A1 (en) * | 1995-06-07 | 1996-12-19 | Cerus Corporation | Treating red blood cell solutions with anti-viral agents |
| US5783584A (en) * | 1995-12-11 | 1998-07-21 | Mayo Foundation For Medical Education And Research | THA analogs useful as cholinesterase inhibitors |
| AU1290700A (en) * | 1998-12-02 | 2000-06-19 | Pfizer Products Inc. | Methods and compositions for restoring conformational stability of a protein of the p53 family |
| US6194403B1 (en) * | 1999-09-09 | 2001-02-27 | Unitech Pharmaceuticals, Inc. | Tacrine derivatives for treating Alzheimer's disease |
-
2004
- 2004-11-18 WO PCT/US2004/038669 patent/WO2005051915A1/en not_active Ceased
- 2004-11-18 CN CNA2004800341960A patent/CN1882546A/zh active Pending
- 2004-11-18 US US10/580,393 patent/US20070099950A1/en not_active Abandoned
- 2004-11-18 EP EP04811391A patent/EP1687275A4/en not_active Withdrawn
- 2004-11-18 CA CA002545786A patent/CA2545786A1/en not_active Abandoned
- 2004-11-18 AU AU2004292546A patent/AU2004292546A1/en not_active Abandoned
- 2004-11-18 JP JP2006541366A patent/JP2007512341A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509150A5 (https=) | ||
| JP2006522128A5 (https=) | ||
| CN101827819B (zh) | 阿片样物质酰胺季铵盐 | |
| US5403847A (en) | Use of α1C specific compounds to treat benign prostatic hyperlasia | |
| CA2478799A1 (en) | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| JP2000507949A (ja) | ピペラジンおよびピペリジン化合物 | |
| US20080108660A1 (en) | Benzimidazolone Carboxylic Acid Derivatives | |
| RS51074B (sr) | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora | |
| JP2007512341A5 (https=) | ||
| PT796846E (pt) | Piridinas 2-aril-substituidas | |
| JP2006526608A5 (https=) | ||
| EP2460791B1 (en) | Indole derivative and pharmacologically acceptable salt thereof | |
| MX2012001275A (es) | Derivado de indol o sal farmaceuticamente aceptable del mismo. | |
| WO1998043978A1 (en) | Morphinane derivatives and medicinal use thereof | |
| MX2009006319A (es) | Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. | |
| JP2005536519A5 (https=) | ||
| PH27115A (en) | 1,4-disubstituted-piperidinyl compounds | |
| JP2004527567A5 (https=) | ||
| JP2003535050A5 (https=) | ||
| US7585974B2 (en) | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | |
| US7737163B2 (en) | Benzimidazolone carboxylic acid derivatives | |
| CA2103974A1 (en) | Pyrrolidine derivatives | |
| JP2008516959A5 (https=) | ||
| JPWO1997005091A1 (ja) | ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 | |
| EP0376358A1 (en) | Muscarinic receptor antagonists |